Results 41 to 50 of about 105,114 (279)

Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation

Journal of Experimental & Clinical Cancer Research, 2012
Objectives To study the hypothesis that gemcitabine treatment augments the chemoresistance to gemcitabine by clusterin (sCLU) upregulation. Clusterin inhibition could augment the chemosensitivity of human pancreatic cancer cells by inhibition of ...
Tang Yong, Liu Fenghua, Zheng Chunning, Sun Shaochuan, Jiang Yingsheng   +4 more
doaj   +1 more source

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine

Scientific Reports, 2022
Chemotherapy is a standard therapy for muscle-invasive bladder cancer (MIBC). However, genomic alterations associated with chemotherapy sensitivity in MIBC have not been fully explored.
Shigehiro Tsukahara, Masaki Shiota, Dai Takamatsu, Shohei Nagakawa, Takashi Matsumoto, Ryo Kiyokoba, Mikako Yagi, Daiki Setoyama, Nozomi Noda, Shinya Matsumoto, Tetsutaro Hayashi, Alberto Contreras-Sanz, Peter C. Black, Junichi Inokuchi, Kenichi Kohashi, Yoshinao Oda, Takeshi Uchiumi, Masatoshi Eto, Dongchon Kang   +18 more
doaj   +1 more source

Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer [PDF]

, 2015
Various regimens including molecular targeted agents have been examined in patients with cisplatin (CDDP)-resistant urothelial cancer (UC). However, some studies have been stopped owing to the development of severe adverse events.
Matsuo, Tomohiro, Ohba, Kojiro, Mitsunari, Kensuke, Asai, Akihiro, Miyata, Yasuyoshi, Sakai, Hideki   +5 more
core   +1 more source

Novel Gemcitabine-Re(I) Bisquinolinyl Complex Combinations and Formulations With Liquid Crystalline Nanoparticles for Pancreatic Cancer Photodynamic Therapy

Frontiers in Pharmacology, 2022
With less than 10% of 5-year survival rate, pancreatic ductal adenocarcinoma (PDAC) is known to be one of the most lethal types of cancer. Current literature supports that gemcitabine is the first-line treatment of PDAC.
Hui Shan Liew, Chun-Wai Mai, Chun-Wai Mai, Mohd Zulkefeli, Thiagarajan Madheswaran, Lik Voon Kiew, Lesley Jia Wei Pua, Ling Wei Hii, Ling Wei Hii, Wei Meng Lim, May Lee Low, May Lee Low   +11 more
doaj   +1 more source

Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. [PDF]

, 2013
Copyright: 2013 Hermann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source ...
Tunici, P, Stephan A. Hahn (423002), Hidalgo Manuel, Annette Bakker (109705), Trabulo Sara M., Hermann, PC, Hahn, SA, Patrizia Tunici (109691), Patrick C. Hermann, Hahn Stephan A., Vandana, M, Sanjeeb K. Sahoo (176483), Sahoo Sanjeeb K., Sainz, B, Sainz Bruno, Anamaria Balic (423000), Garcia Elena, Tunici Patrizia, Manuel Hidalgo, Balic, A, Balic Anamaria, Stephan A. Hahn, Vandana Mallaredy, Elena Garcia (423001), Stephan A Hahn, Christopher Heeschen (373899), Sahoo, SK, Patrizia Tunici, Bakker Annette, Mallaredy Vandana, Heeschen Christopher, Patrick C Hermann, Bruno Sainz, Sara M Trabulo, Sara M. Trabulo, Christopher Heeschen, Patrick C. Hermann (422997), Garcia, E, Mallaredy Vandana (423003), Elena Garcia, Sanjeeb K Sahoo, Heeschen, C, Manuel Hidalgo (7235), Bakker, A, Bruno Sainz Jr (422999), Sanjeeb K. Sahoo, Hermann Patrick C., Sara M. Trabulo (422998), Trabulo, SM, Anamaria Balic, Hidalgo, M, Annette Bakker   +51 more
core   +2 more sources

SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling

Bangladesh Journal of Pharmacology
Gemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients.
Hao Yu, Xiaoping Mei, Xueming Zhang, Neng Qian, Qingjiang Yu, Hongkun Zhou   +5 more
doaj   +1 more source

Hypomethylation of GNA15 Promotes Pancreatic Ductal Adenocarcinoma Progression and Macrophage M2 Polarization via STAT3-CXCL8 Axis. [PDF]

Adv Sci (Weinh)
A schematic model summarizing GNA15's mechanism in mediating macrophage M2 polarization and Gemcitabine resistance. ABSTRACT The complexity of pancreatic ductal adenocarcinoma (PDAC) progression, coupled with the lack of effective immunotherapy, underscores the imperative to deepen our understanding of its mechanisms and identify suitable immune ...
Guo W, Qian Z, Wang L, Xu W, Weng Y, Jiang K, Ye Z, Xu J, Song G.   +8 more
europepmc   +2 more sources

Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway. [PDF]

PLoS ONE, 2016
Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs.
Zhen-Hua Wu, Chen Lin, Ming-Ming Liu, Jian Zhang, Zhong-Hua Tao, Xi-Chun Hu   +5 more
doaj   +1 more source

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison

BMC Cancer, 2008
Background Recent meta-analyses have found a survival advantage with gemcitabine based combinations over single agent gemcitabine in patients with advanced pancreatic cancer.
Neoptolemos John P, Starling Naureen, Cunningham David, Ghaneh Paula, Sultana Asma, Smith Catrin   +5 more
doaj   +1 more source

Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study

BMC Cancer, 2020
Background Undifferentiated carcinoma (UC) of the pancreas is a rare subtype of pancreatic cancer. Although UC has been considered a highly aggressive malignancy, no clinical studies have addressed the efficacy of chemotherapy for unresectable UC ...
Hiroshi Imaoka, Masafumi Ikeda, Kosuke Maehara, Kumiko Umemoto, Masato Ozaka, Satoshi Kobayashi, Takeshi Terashima, Hiroto Inoue, Chihiro Sakaguchi, Kunihiro Tsuji, Kazuhiko Shioji, Keiya Okamura, Yasuyuki Kawamoto, Rei Suzuki, Hirofumi Shirakawa, Hiroaki Nagano, Makoto Ueno, Chigusa Morizane, Junji Furuse   +18 more
doaj   +1 more source